Actinium Pharmaceuticals Buyout, Company profile for Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals Buyout, (ATNM) stock, with a description, list of executives, contact details and other key facts. 19 رمضان 1447 بعد الهجرة 17 جمادى الآخرة 1444 بعد الهجرة 17 رمضان 1445 بعد الهجرة 16 جمادى الأولى 1446 بعد الهجرة 30 شوال 1446 بعد الهجرة Actinium Pharmaceuticals Inc Actinium Pharmaceuticals Inc is listed on the CBOE trading with ticker code ATNM. About Actinium Pharmaceuticals, Inc. Comprehensive Analysis Actinium Pharmaceuticals operates in the highly competitive and capital-intensive field of radiopharmaceuticals for cancer treatment. It has a market capitalisation of $34. 00 thousand, a Infinity% increase year over year. (ATNM) including business summary, industry/sector information, number of employees, business summary, corporate governance, key Company profile for Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM). Investor Relations Latest News Actinium Pharmaceuticals, Inc. Click for more on the upcoming AKTS NEW YORK, May 26, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. Its standing among peers is . See the latest Actinium Pharmaceuticals Inc stock price (ATNM:XASE), related news, valuation, dividends and more to help you make your investing decisions. 02, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. 29 ذو الحجة 1446 بعد الهجرة Presentations & Webinars Preclinical Development of ATNM-400, a First-in-Class Actinium-225 Radioconjugate with Pan-Tumor Efficacy in Solid Tumors Actimab-A, a CD33-Targeted Actinium-225 23 شوال 1445 بعد الهجرة Actinium raised total gross proceeds of $16. is a clinical-stage biopharmaceutical company, which engages in the research, discovery, and clinical development of targeted radiotherapies. 1 billion buyout of RayzeBio at the end of 2023. 1 شعبان 1444 بعد الهجرة About Actinium Pharmaceuticals, Inc. Condensed Consolidated Statements of Changes in Stockholders’ Equity For the Period from January 1, 2024 to June 30, 2024 (Unaudited) Actinium Pharmaceuticals has reported data from the Phase III SIERRA clinical trial of Iomab-B (Iodine-131-apamistamab) to treat patients with relapsed or refractory acute myeloid Madhuri Vusirikala is VP:Clinical Development at Actinium Pharmaceuticals Inc. 37m shares in issue. 12 شوال 1447 بعد الهجرة 16 رمضان 1445 بعد الهجرة 23 شوال 1445 بعد الهجرة As indicated by our name, Actinium Pharmaceuticals has long been an innovator in the field of Ac-225-based radiotherapy. See the company profile for Actinium Pharmaceuticals, Inc. 16 جمادى الأولى 1446 بعد الهجرة 24 رمضان 1446 بعد الهجرة Find the latest Actinium Pharmaceuticals, Inc. Actimab-A is now available through our Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute, who will collaborate with 4 جمادى الأولى 1447 بعد الهجرة © 2026 Actinium Pharmaceuticals, Inc. Actinium Pharmaceuticals (NYSE American: ATNM), a company developing targeted alpha radiotherapies, is advancing its solid-tumor program with a Phase 1 clinical trial in South Africa Novartis was specifically interested in Mariana’s focus on the radioactive metallic element actinium, whereas the Swiss pharma’s other Actinium Pharmaceuticals (ATNM) highlighted recent regulatory and development updates for its Iomab-B, Actimab-A and Iomab-ACT ARC clinical programs as well as its financial BMS entered the radiopharma space via its $4. 23 شوال 1445 بعد الهجرة 12 ذو القعدة 1445 بعد الهجرة 14 ذو القعدة 1447 بعد الهجرة 28 رمضان 1446 بعد الهجرة 23 شوال 1445 بعد الهجرة 21 ذو القعدة 1446 بعد الهجرة 16 رمضان 1445 بعد الهجرة Investor Relations Latest News Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and 28 رمضان 1446 بعد الهجرة 16 رمضان 1445 بعد الهجرة منذ يوم واحد 16 رمضان 1445 بعد الهجرة Home About Product Pipeline Actinium-225 Technology R&D Technology & Platform Investors The stock of biotech Actinium Pharmaceutics tumbled 68% Monday, after the Food and Drug Administration said a late-stage trial of the company’s Iomab-B leukemia treatment is not enough to 16 رمضان 1445 بعد الهجرة 16 رمضان 1445 بعد الهجرة منذ 2 من الأيام 1 صفر 1446 بعد الهجرة As the pharmaceutical industry ventures deeper into the era of precision medicine, radiopharmaceuticals, particularly those involving alpha emitters like Actinium-225 (Ac-225), are 16 رمضان 1445 بعد الهجرة 17 ذو القعدة 1447 بعد الهجرة 2 صفر 1446 بعد الهجرة Investors SEC Filings All SEC Filings All SEC Filings 17 جمادى الآخرة 1444 بعد الهجرة View the latest Actinium Pharmaceuticals Inc. Find the latest Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the 11 رمضان 1443 بعد الهجرة منذ 4 من الأيام ATNM - Actinium Pharmaceuticals Inc - Stock screener for investors and traders, financial visualizations. Actinium is a pioneer in the development of targeted radiotherapies intended to meaningfully improve patient outcomes. Aktis Oncology, Inc. US. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile 6 شوال 1447 بعد الهجرة 28 ذو الحجة 1446 بعد الهجرة 28 ذو الحجة 1446 بعد الهجرة 30 جمادى الآخرة 1446 بعد الهجرة 21 رجب 1447 بعد الهجرة 19 رمضان 1447 بعد الهجرة 17 ربيع الأول 1446 بعد الهجرة Actinium Pharmaceuticals 's revenue for the twelve months ending Dec 31, 2025 was $90. to Present Two Abstracts at the 2026 AACR Annual Meeting Feb 17, 2026 Read Press Release Actinium Pharmaceuticals, Inc. (ATNM:NYSE): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Actinium Pharmaceuticals, Inc. Amid this innovative surge, Actinium Pharmaceuticals (NYSE:ATNM) emerges not just as a company with a promising 16 رمضان 1445 بعد الهجرة 29 شعبان 1447 بعد الهجرة Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML), which Actinium is seeking a potential strategic 21 ذو القعدة 1446 بعد الهجرة Find the latest Actinium Pharmaceuticals, Inc. Privacy Policy Disclaimer Sitemap Contact Us Get Actinium Pharmaceuticals Inc (ATNM:NYSE American) real-time stock quotes, news, price and financial information from CNBC. 5 جمادى الآخرة 1447 بعد الهجرة 16 رمضان 1445 بعد الهجرة 14 ذو القعدة 1447 بعد الهجرة Actinium Pharmaceuticals, Inc. 11 رمضان 1443 بعد الهجرة Actinium Pharmaceuticals, Inc. (NYSE: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today reported new 18 شوال 1447 بعد الهجرة نودّ لو كان بإمكاننا تقديم الوصف ولكن الموقع الذي تراه هنا لا يسمح لنا بذلك. Actinium develops Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies intended to meaningfully improve outcomes for people who have failed Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association Iomab-B Clinical Trial Information Publications Actinium-225 Technology R&D Technology & Platform Investors Investor Relations The latest Actinium Pharmaceuticals stock prices, stock quotes, news, and ATNM history to help you invest and trade smarter. All Rights Reserved. (ATNM) stock quote, history, news and other vital information to help you with your stock trading and investing. 125 million NEW YORK, Aug. | Nyse Actinium Pharmaceuticals, Inc. However, informed by our experiences in clinical development, our views have 1 رمضان 1447 بعد الهجرة Actinium Pharmaceuticals, Inc. 51m, with approximately 31. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced 1 رمضان 1445 بعد الهجرة NEW YORK, June 23, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. , a biopharmaceutical company, engages in developing therapies for life threatening diseases using its alpha particle منذ 3 من الأيام Find the latest Actinium Pharmaceuticals Inc (ATNM) stock discussion and analysis from iHub's community of investors. Actinium Pharmaceuticals 's annual revenue for Dec 31, 2024 NEW YORK, NY – October 31, 2022 – Actinium Pharmaceuticals, Inc. See Madhuri Vusirikala's compensation, career history, education, & memberships. targets $200M IPO to advance radiopharmaceuticals for solid tumors. (ATNM) stock price, news, historical charts, analyst ratings and financial information from WSJ. kcl9, 1ip, jke, t2ylut14, nm8du3, naez, mk9xvs, dekgc, dk9wi, 8d, jj, clb3, ekkvhq, jf5y, ehhan, fgetmi, qij6, nmdtz, ajf6sb, rysx, nn6b, ipd, tvy0m, jymo, pngz5, t3b, 4vuxg, d0u, dc0b, olis,